Puma Biotechnology (PBYI) Change in Receivables (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly Change in Receivables came in at -$27.3 million in Q1 2026, down 312.39% YoY from $12.9 million in Q1 2025, and down 236.02% on a QoQ basis from $20.1 million in Q4 2025.
Puma Biotechnology (PBYI) Change in Receivables (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of Change in Receivables data on file, last reported at -$27.3 million in Q1 2026.
- Quarterly Change in Receivables fell 312.39% year-over-year to -$27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582000.0 (up 238.37% YoY) and the FY2025 annual result came in at $21.3 million, up 230.2% from the prior year.
- Change in Receivables slipped to -$27.3 million in Q1 2026, from $20.1 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $26.5 million in Q3 2024 to a low of -$27.3 million in Q1 2026.
- A 5-year average of -$364529.4 and a median of $376000.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 992.2% — and 2024, when it surged 1243.78%.
- Tracing PBYI's Change in Receivables over 5 years: stood at $12.3 million in 2022, then soared by 56.09% to $19.2 million in 2023, then tumbled by 219.76% to -$23.0 million in 2024, then surged by 187.23% to $20.1 million in 2025, then plunged by 236.02% to -$27.3 million in 2026.
- The last three Change in Receivables figures came in at -$27.3 million (Q1 2026), $20.1 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 7.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.73 Mn |
| Jun 30, 2026 | 7.73 Mn |
| Mar 31, 2026 | -27.33 Mn |
| Mar 31, 2026 | -27.33 Mn |
| Dec 31, 2025 | 20.09 Mn |
| Dec 31, 2025 | 20.09 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 376,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | -6.63 Mn |
| Mar 31, 2025 | -6.63 Mn |
| Dec 31, 2024 | -23.03 Mn |
| Dec 31, 2024 | -23.03 Mn |
| Sep 30, 2024 | 26.49 Mn |
| Sep 30, 2024 | 26.49 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | -23.14 Mn |
| Mar 31, 2024 | -23.14 Mn |